PMID- 16984392
OWN - NLM
STAT- MEDLINE
DCOM- 20061214
LR  - 20171116
IS  - 0007-1048 (Print)
IS  - 0007-1048 (Linking)
VI  - 135
IP  - 3
DP  - 2006 Nov
TI  - Development of autologous cytotoxic CD4+ T clones in a human model of B-cell 
      non-Hodgkin follicular lymphoma.
PG  - 324-35
AB  - Immunotherapy for cancer aims to generate cytotoxic cells that are capable of 
      eradicating tumour cells. It has been well demonstrated that helper, 
      non-cytotoxic CD4(+) T cells are important for the induction and maintenance of 
      anti-tumour immunity exerted by cytotoxic CD8(+) T cells. In contrast, the 
      existence of direct anti-tumour, effector cytotoxic CD4(+) T cells remains 
      elusive, mainly due to the paucity of reliable experimental data, especially in 
      human B-cell non-Hodgkin lymphomas. This study developed an appropriate, 
      autologous follicular B-cell non-Hodgkin follicular lymphoma model, including the 
      in vitro establishment of a malignant, human leucocyte antigen class I (HLA-I) 
      deficient B-cell line, and the generation of three autologous anti-tumour 
      cytotoxic CD4(+) T-cell clones originating from the peripheral blood of the same 
      patient. These three clones were considered as tumour specific, because they were 
      capable of killing the malignant, HLA-I-deficient B-cell line through a classical 
      HLA-II restricted perforin-mediated pathway, but did not lyse the Epstein-Barr 
      virus-infected autologous normal B lymphocytes. All three CD4(+)clones were 
      T-cell receptor Vbeta17-Dbeta1-Jbeta1.2 and exhibited an identical 
      complementarity-determining region 3, suggesting the immunodominance of a single 
      peptide antigen presented by tumour cells. Such lymphoma models would provide a 
      useful tool for in vivo expansion and the adoptive transfer of selected CD4(+) 
      cytotoxic cells in immunotherapeutic strategies.
FAU - Mi, Jian-Qing
AU  - Mi JQ
AD  - Institut National de la Sante et de la Recherche Medicale [Inserm E353, Lymphoma 
      Research Group (Molecular Bases of Tumor Progression)], Universite Joseph 
      Fourier, La Tronche, France. jian-qing.mi@ujf-grenoble.fr
FAU - Manches, Olivier
AU  - Manches O
FAU - Wang, Jin
AU  - Wang J
FAU - Perron, Pascal
AU  - Perron P
FAU - Weisbuch, Sebastien
AU  - Weisbuch S
FAU - Marche, Patrice N
AU  - Marche PN
FAU - Renversez, Jean-Charles
AU  - Renversez JC
FAU - Bensa, Jean-Claude
AU  - Bensa JC
FAU - Sotto, Jean-Jacques
AU  - Sotto JJ
FAU - Cahn, Jean-Yves
AU  - Cahn JY
FAU - Leroux, Dominique
AU  - Leroux D
FAU - Bonnefoix, Thierry
AU  - Bonnefoix T
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20060919
PL  - England
TA  - Br J Haematol
JT  - British journal of haematology
JID - 0372544
RN  - 0 (Antigens, CD)
RN  - 0 (CD3 Complex)
RN  - 0 (Cytokines)
RN  - 0 (Histocompatibility Antigens Class I)
RN  - 0 (Histocompatibility Antigens Class II)
RN  - 0 (Receptors, Antigen, T-Cell)
SB  - IM
MH  - Antigens, CD/immunology
MH  - CD3 Complex/immunology
MH  - CD4-Positive T-Lymphocytes/*immunology
MH  - Cell Division/immunology
MH  - Cell Line, Tumor
MH  - Clone Cells/immunology
MH  - Cytokines/immunology
MH  - Cytotoxicity, Immunologic/immunology
MH  - Histocompatibility Antigens Class I/immunology
MH  - Histocompatibility Antigens Class II/immunology
MH  - Humans
MH  - Lymphoma, B-Cell/*immunology
MH  - Lymphoma, Follicular/*immunology
MH  - Models, Biological
MH  - Receptors, Antigen, T-Cell/immunology
MH  - T-Lymphocytes, Helper-Inducer/immunology
EDAT- 2006/09/21 09:00
MHDA- 2006/12/15 09:00
CRDT- 2006/09/21 09:00
PHST- 2006/09/21 09:00 [pubmed]
PHST- 2006/12/15 09:00 [medline]
PHST- 2006/09/21 09:00 [entrez]
AID - BJH6294 [pii]
AID - 10.1111/j.1365-2141.2006.06294.x [doi]
PST - ppublish
SO  - Br J Haematol. 2006 Nov;135(3):324-35. doi: 10.1111/j.1365-2141.2006.06294.x. 
      Epub 2006 Sep 19.